Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 4/20 | 0.32 |
| ▸ | GABRD | O14764 | 4/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20751905 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL6672007 | 0.86 | ALDH1A1 (0.62) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL3580171 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL13502386 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL4961818 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL12938000 | 0.79 | ALDH1A1 (0.37) | ALDH1A1MAPTPTGS1SLC7A5DPP4 | |
| SCHEMBL14702337 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1SLC7A5DPP4 | |
| SCHEMBL6263555 | 0.75 | ALDH1A1 (0.62) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL7396758 | 0.75 | ALDH1A1 (0.62) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL6433 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284611-A1 | ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2023-01-19 | — | — | WO | disclosed |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| WO-2011058165-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011033068-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | ALDH1A1 4710/4885MAPT 2741/4885PTGS1 855/4885 |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | ALDH1A1 4829/4885MAPT 3574/4885PTGS1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.